WinSanTor cover feature

WinSanTor

Ensuring no one suffers from Peripheral Neuropathy
$591,649 Raised
Ended March 21st
283 Investors

Peripheral neuropathy (PN) is one of the most significant unmet needs today, affecting 1 in 15 in the U.S. PN is the dying of nerves caused by many major diseases or injuries, e.g., diabetes, cancer/chemo, HIV, and genetic diseases. There is currently no treatment, only pain drugs that reduce all feeling. We are now in trials showing that we may be on track to reverse the disease, both biologically and functionally and, most importantly, to improve the quality-of-life for the millions affected.

Why you may want to invest
  1. CEO's prior two companies were acquired by Qualcomm and Apple, with technologies now standards in the industry.

  2. Over $30M of non-dilutive funding (peer-reviewed grants rewarding innovation above 'hot' target trends) has driven the research and development.

  3. Extensive evidence, including a proof-of-concept study in humans, showing a reversal of PN through 1) nerve regrowth, 2) reduced symptoms, and 3) return of quality-of-life to patients.

  4. Having completed Phase 1 safety studies, we're entering Phase 2 early efficacy studies this year for our lead drug, WST-057, a study funded by the Canadian government.

  5. The active ingredient in our drug is a historically safe drug used for 30+ years that is being 'recycled' to get to patients faster - increasing safety and lowering development cost and time.

  6. Assemblage of nearly every stakeholder in diabetic peripheral neuropathy (DPN): clinicians, researchers, non-profits, governments, and, critically, patients.

  7. To date, we have no outside investors. Our only true investors are our service providers, friends & family, and potential patients - all stakeholders who like where we are going.

  8. The valuation of past companies attempting to treat DPN was several hundred million dollars after Phase 1 and several billion dollars after Phase 2.

Learn more about this company

Company Details

Location
San Diego, CA
Founded
2011
Employees
5

Key Team Members

Lakshmi P. Kotra
Director
Andrew Albertson
Controller
Paul Fernyhough
Director

Financials

Most recent Fiscal Year

Income Statement

Revenue
41%
$1,558,270
Cost of Goods Sold
$0
Gross Profit
41%
$1,558,270
Taxes
12330%
-$168,163
Net Income
316%
-$581,563

Balance Sheet

Total Assets
45%
$116,234
Cash
148%
$109,627
Accounts Receivable
5%
$1,577
Short Term Debt
44%
$319,672
Long Term Debt
6%
$450,000

Other popular startups

Get email updates for the latest investment opportunities
Email
Email